Related Experiment Video
Updated: Feb 15, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Carbon nanospheres mediated nuclear delivery of SMAR1 protein (DNA binding domain) controls breast tumor in mice
Prasad N Bhagat1, Sachin H Jadhav1, Samit Chattopadhyay2
1Agharkar Research Institute, G. G. Agarkar Road, Pune 411004, Maharashtra, India.
Aim:
To investigate anticancer activity of the DNA binding domain of SMAR1 (His 5) in vitro and in vivo.
Materials & Methods:
His 5 was conjugated to hydrothermally synthesized carbon nanospheres (CNs). Anticancer activity of CNs-His 5 was evaluated in vitro and in vivo.
Results:
CNs- His 5 significantly reduced cyclin D1 levels in MDA-MB-231 cells. Tumor bearing Balb/c mice injected with CNs-His 5 showed approximately 62% tumor regression and significantly reduced 18FDG uptake. Caspases assay and IHC staining confirmed tumor growth inhibition, which could be attributed to apoptotic, antiproliferative and antiangiogenic activities of His 5.
Conclusion:
DNA binding domain of the SMAR1 protein (His 5) has potent anticancer activity and its CNs mediated delivery could control breast tumor in mice model.
Insights
The DNA binding domain of SMAR1 protein (His 5), when delivered via carbon nanospheres (CNs), demonstrated significant anticancer activity. This novel approach effectively controlled breast tumor growth in a mouse model.
Area of Science:
- Oncology
- Nanotechnology
- Molecular Biology
Background:
- The SMAR1 protein plays a role in gene regulation.
- Targeting cancer with novel drug delivery systems is crucial.
Purpose of the Study:
- To evaluate the anticancer potential of the SMAR1 DNA binding domain (His 5).
- To assess the efficacy of carbon nanosphere (CNs)-mediated delivery of His 5 for cancer treatment.
Main Methods:
- His 5 was conjugated to hydrothermally synthesized carbon nanospheres (CNs).
- In vitro and in vivo anticancer activity of CNs-His 5 was evaluated.
- Tumor regression, 18FDG uptake, caspase assays, and IHC staining were analyzed.
Main Results:
- CNs-His 5 significantly reduced cyclin D1 levels in MDA-MB-231 cells.
- A 62% tumor regression was observed in tumor-bearing mice treated with CNs-His 5.
- Tumor growth inhibition was confirmed via caspase assays and IHC staining, indicating apoptotic, antiproliferative, and antiangiogenic effects.
Conclusions:
- The DNA binding domain of SMAR1 (His 5) exhibits potent anticancer properties.
- CNs-mediated delivery of His 5 offers a promising strategy for controlling breast tumors.
More Related Videos
Related Concept Videos
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
Nuclear Binding Energy
Single-Strand DNA Binding Proteins
From DNA to Protein
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Conservation of Protein Domains

